Company news: KV Pharmaceuticals, Elsevier, Pfizer

Share this article:
KV pharmaceuticals, which declared bankruptcy last week, has chalked up a win in the Georgia courts. A US district court ruled that the Georgia Medicaid program was unfairly sidelining the FDA-approved drug by requiring pre-authorization before patients could receive KV's drug Makena, as reported by Forbes. The court said the pre-approval policy ends up favoring compounded versions of the drug over the FDA-approved one, which is meant to reduce the risk of premature births.

Dutch publisher Elsevier has paired up with Follett Higher Education group. The collaboration will make the publisher's digital Pageburst titles available through Follett's network of academic bookstores, which includes 900 colleges and universities in the US and Canada.

Pfizer continued to power ahead with plans for spinning off its animal health business, Zoetis. The company announced Monday it filed the paperwork with the SEC to pave the way for the unit's IPO. Plans are to put about 20% of the company up for grabs. The IPO is expected early next year.

Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.